Literature DB >> 35023278

Factor XI as a target for preventing venous thromboembolism.

David Gailani1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35023278      PMCID： PMC9540353          DOI： 10.1111/jth.15628

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   16.036


× No keyword cloud information.
  44 in total

Review 1.  Rare bleeding disorders - bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency.

Authors:  P James; O Salomon; D Mikovic; F Peyvandi
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

2.  Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor.

Authors:  M C Minnema; P W Friederich; M Levi; P A von dem Borne; L O Mosnier; J C Meijers; B J Biemond; C E Hack; B N Bouma; H ten Cate
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

3.  Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates.

Authors:  Andras Gruber; Stephen R Hanson
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

4.  Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.

Authors:  Jeffrey I Weitz; Rupert Bauersachs; Bastian Becker; Scott D Berkowitz; Maria C S Freitas; Michael R Lassen; Carola Metzig; Gary E Raskob
Journal:  JAMA       Date:  2020-01-14       Impact factor: 56.272

5.  A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors.

Authors:  Ophira Salomon; David Gailani
Journal:  J Thromb Haemost       Date:  2021-11-21       Impact factor: 16.036

6.  The Association between Factor XI Deficiency and the Risk of Bleeding, Cardiovascular, and Venous Thromboembolic Events.

Authors:  Sarah Sharman Moser; Gabriel Chodick; Yan G Ni; Dan Chalothorn; Ming-Dauh Wang; Alan R Shuldiner; Lori Morton; Ophira Salomon; Jessica J Jalbert
Journal:  Thromb Haemost       Date:  2021-09-23       Impact factor: 6.681

7.  Factor XI antisense oligonucleotide for prevention of venous thrombosis.

Authors:  Harry R Büller; Claudette Bethune; Sanjay Bhanot; David Gailani; Brett P Monia; Gary E Raskob; Annelise Segers; Peter Verhamme; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2014-12-07       Impact factor: 91.245

8.  Prospective study of circulating factor XI and incident venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE).

Authors:  Aaron R Folsom; Weihong Tang; Nicholas S Roetker; Susan R Heckbert; Mary Cushman; James S Pankow
Journal:  Am J Hematol       Date:  2015-11       Impact factor: 10.047

9.  Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits.

Authors:  Pancras C Wong; Earl J Crain; Jeffrey M Bozarth; Yiming Wu; Andrew K Dilger; Ruth R Wexler; William R Ewing; David Gordon; Joseph M Luettgen
Journal:  J Thromb Haemost       Date:  2021-11-24       Impact factor: 16.036

10.  Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa.

Authors:  B Alexander Yi; Debra Freedholm; Nancy Widener; Xiaohui Wang; Emilie Simard; Constance Cullen; Naab M Al-Saady; Norman E Lepor; Sara Coulter; Mark Lovern; Dan Bloomfield
Journal:  J Thromb Haemost       Date:  2021-11-19       Impact factor: 16.036
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.